In the past few years, the united kingdom has witnessed a revolution in clinical body weight‑decline treatments — from the introduction of semaglutide (Wegovy®) towards the escalating recognition of tirzepatide (Mounjaro®). Now, Yet another identify is drawing consideration in the two scientific